Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001091624 | SCV001247773 | pathogenic | not provided | 2019-04-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005089168 | SCV005835850 | pathogenic | Charcot-Marie-Tooth disease type 2 | 2024-11-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr106Cysfs*6) in the BSCL2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BSCL2 are known to be pathogenic (PMID: 11479539, 23564749). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with autosomal recessive BSCL2-related conditions (PMID: 11479539, 23564749). This variant is also known as 659delGTATC, F105fs, c.507_511del. ClinVar contains an entry for this variant (Variation ID: 4535). For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000004793 | SCV000024969 | pathogenic | Congenital generalized lipodystrophy type 2 | 2007-12-26 | no assertion criteria provided | literature only | |
OMIM | RCV000133399 | SCV000188472 | pathogenic | Severe neurodegenerative syndrome with lipodystrophy | 2013-06-01 | no assertion criteria provided | literature only | |
Gene |
RCV000004793 | SCV000490132 | not provided | Congenital generalized lipodystrophy type 2 | no assertion provided | literature only | ||
Inherited Neuropathy Consortium Ii, |
RCV003311638 | SCV004011973 | uncertain significance | Berardinelli-Seip congenital lipodystrophy | 2016-01-06 | no assertion criteria provided | literature only |